,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Neratinib,Acarbose,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and microbial flora. Neratinib is unlikely to interfere with this metabolic pathway. ",See Summary
1,Neratinib,Acenocoumarol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolised by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Neratinib does not inhibit or induce CYPs.,See Summary
2,Neratinib,Acetylsalicylic acid (Aspirin),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid and then further metabolised by glucuronidation (by several UGTs, major UGT1A6). Neratinib does not inhibit or induce UGTs.",See Summary
3,Neratinib,Agomelatine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2 (90%), with a small proportion metabolised by CYP2C9 and CYP2C19 (10%). Neratinib does not inhibit or induce CYPs.",See Summary
4,Neratinib,Alendronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alendronate is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, alendronate should be separated from food or other medicinal products and patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.",See Summary
5,Neratinib,Alfentanil,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. Neratinib does not inhibit or induce CYPs.,See Summary
6,Neratinib,Alfuzosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolised by CYP3A. Neratinib does not inhibit or induce CYPs.,See Summary
7,Neratinib,Aliskiren,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Aliskiren is minimally metabolised and is mainly excreted unchanged in faeces. Aliskiren is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Concentrations of aliskiren may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring of blood pressure should be considered.",See Summary
8,Neratinib,Allopurinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Neratinib does not interact with this metabolic pathway.,See Summary
9,Neratinib,Alosetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that alosetron is metabolised by CYPs 2C9, 3A4 and 1A2. Neratinib does not inhibit or induce CYPs.",See Summary
10,Neratinib,Alprazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
11,Neratinib,Aluminium hydroxide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be avoided. Aluminium hydroxide is not metabolised. The absorption of neratinib decreases when used concomitantly with antacids, leading to decreased neratinib exposure. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at least 3 hours after aluminium hydroxide.",See Summary
12,Neratinib,Ambrisentan,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ambrisentan is metabolised by glucuronidation via UGTs 1A3, 1A9 and 2B7, and to a lesser extent by CYP3A4 and CYP2C19. Ambrisentan is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Concentrations of ambrisentan may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring of blood pressure should be considered.",See Summary
13,Neratinib,Amikacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amikacin is eliminated by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
14,Neratinib,Amiloride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged in the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Neratinib does not inhibit or induce OCT2.,See Summary
15,Neratinib,Amiodarone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Amiodarone is metabolised by CYP3A4 and CYP2C8. Neratinib does not inhibit or induce CYPs. However, the major metabolite of amiodarone, desethylamiodarone, is an inhibitor of CYPs 3A4 (weak), 2C9 (moderate), 2D6 (moderate), 2C19 (weak), 1A1 (strong) and 2B6 (moderate). Concentrations of neratinib may decrease due to weak inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity is recommended. Due to the long half-life of amiodarone, interactions can be observed for several months after discontinuation of amiodarone. ",See Summary
16,Neratinib,Amisulpride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolised and is primarily renally eliminated (possibly via OCT). Neratinib is unlikely to interact with this elimination pathway.,See Summary
17,Neratinib,Amitriptyline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19, with a small proportion metabolised by CYPs 3A4, 1A2 and 2C9. Neratinib does not inhibit or induce CYPs.",See Summary
18,Neratinib,Amlodipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
19,Neratinib,Amoxicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
20,Neratinib,Amphotericin B,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amphotericin B is not appreciably metabolised but is eliminated to a large extent in the bile. Neratinib does not interfere with this elimination pathway. However, the European SPC for amphotericin B states that concomitant use of amphotericin B and antineoplastic agents can increase the risk of renal toxicity, bronchospasm and hypotension and so monitoring may be required.",See Summary
21,Neratinib,Ampicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. About 20-40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60-80% is excreted in the urine within 6 hours. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
22,Neratinib,Anidulafungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperatures. ,See Summary
23,Neratinib,Antacids,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be avoided. Antacids are not metabolised by CYPs. Neratinib is unlikely to interfere with this metabolic pathway. However, the absorption of neratinib decreases when used concomitantly with antacids, leading to decreased neratinib exposure. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at least 3 hours after antacids.",See Summary
24,Neratinib,Apixaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Apixaban is a substrate of P-gp and BCRP, and is also metabolised by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8, 2C9 and 2C19. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for apixaban toxicity is recommended.",See Summary
25,Neratinib,Aprepitant,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Neratinib does not inhibit or induce CYPs. However, during treatment aprepitant is a moderate inhibitor of CYP3A4. Concentrations of neratinib may increase during the three days of coadministration due to CYP3A4 inhibition. Coadministration should be approached with caution. If coadministration is unavoidable, monitor closely for neratinib toxicity. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of neratinib may decrease due to CYP3A4 induction, but this is unlikely to be of clinical relevance.",See Summary
26,Neratinib,Aripiprazole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolised by CYP3A4 and CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
27,Neratinib,Asenapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolised by glucuronidation (UGT1A4) and oxidative metabolism (CYPs 1A2 (major), 3A4 and 2D6 (minor)). Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
28,Neratinib,Astemizole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Astemizole is metabolised by CYPs 2D6, 2J2 and 3A4. Neratinib does not inhibit or induce CYPs.",See Summary
29,Neratinib,Atenolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
30,Neratinib,Atorvastatin,"
Potential Weak Interaction
","
Very Low
",Coadministration has not been studied. Atorvastatin is metabolised by CYP3A4 and is a substrate of P-gp and OATP1B1. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Atorvastatin concentrations may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. It should be considered to start with the lowest dose of atorvastatin and titrate up to the desired clinical effect while monitoring for safety.,See Summary
31,Neratinib,Azathioprine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolised analogously to natural purines. Neratinib does not interact with this metabolic pathway.,See Summary
32,Neratinib,Azithromycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion; animal data suggest this may occur via P-gp and MRP2. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. A clinically relevant interaction is unlikely.,See Summary
33,Neratinib,Beclometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate. Neratinib does not interact with this metabolic pathway.",See Summary
34,Neratinib,Bedaquiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bedaquiline is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
35,Neratinib,Bendroflumethiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically relevant interaction is unlikely in the range of observed clinical concentrations. Neratinib does not interact with this pathway.,See Summary
36,Neratinib,Bepridil,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bepridil is metabolised by CYP2D6 (major) and CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
37,Neratinib,Betamethasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betamethasone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
38,Neratinib,Bezafibrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of a bezafibrate dose is eliminated unchanged in the urine. Neratinib is unlikely to interfere with this elimination pathway. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1. Neratinib is not a substrate of OAT1.,See Summary
39,Neratinib,Bisacodyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Neratinib does not interact with this metabolic pathway.,See Summary
40,Neratinib,Bisoprolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolised by CYP3A4 and CYP2D6, and partly eliminated unchanged in the urine. Neratinib does not inhibit or induce CYPs and is unlikely to interfere with the elimination of bisoprolol.",See Summary
41,Neratinib,Bosentan,"
Potential Interaction
","
Low
","Coadministration has not been studied but should be approached with caution. Bosentan is a substrate of CYP3A4 and CYP2C9. Neratinib does not inhibit or induce CYPs. However, bosentan is a weak inducer of CYP3A4 and CYP2C9. Concentrations of neratinib may decrease due to CYP3A4 inhibition. Imatinib concentrations, on average, decreased by 33% in the presence of bosentan in a phase III clinical study and a similar effect may occur with neratinib. If coadministration appears necessary, close monitoring is needed.",See Summary
42,Neratinib,Bromazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Neratinib does not inhibit or induce CYPs.",See Summary
43,Neratinib,Budesonide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
44,Neratinib,Buprenorphine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Neratinib does not inhibit or induce CYPs or UGTs.,See Summary
45,Neratinib,Bupropion,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolised by CYP2B6 and is a strong inhibitor of CYP2D6. Neratinib does not interact with this metabolic pathway.,See Summary
46,Neratinib,Buspirone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
47,Neratinib,Calcium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat. Neratinib does not interfere with this elimination pathway.",See Summary
48,Neratinib,Candesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. Neratinib is unlikely to interact with this elimination pathway.,See Summary
49,Neratinib,Capreomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
50,Neratinib,Captopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Neratinib does not inhibit or induce OAT1.,See Summary
51,Neratinib,Carbamazepine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Carbamazepine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2C8. Neratinib does not inhibit or induce CYPs. However, carbamazepine is an inducer of CYPs 2C8 (strong), 2C9 (strong), 3A4 (strong), 1A2 (weak), 2B6 and UGT1A1. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with carbamazepine. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
52,Neratinib,Carvedilol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additional metabolism via CYP2D6 and to a lesser extent by CYPs 2C9 and 1A2. Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
53,Neratinib,Caspofungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. Neratinib does not interfere with this metabolic pathway.,See Summary
54,Neratinib,Cefalexin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly renally eliminated unchanged by glomerular filtration and tubular secretion via OAT1 and MATE1. Neratinib does not inhibit or induce OAT1 or MATE1 and is unlikely to interfere with this elimination pathway.,See Summary
55,Neratinib,Cefazolin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
56,Neratinib,Cefixime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
57,Neratinib,Cefotaxime,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolised by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
58,Neratinib,Ceftazidime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway. ,See Summary
59,Neratinib,Ceftriaxone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
60,Neratinib,Celecoxib,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolised by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
61,Neratinib,Cetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine is also an inhibitor of OCT2. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
62,Neratinib,Chloramphenicol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Chloramphenicol is predominantly glucuronidated. Neratinib does not inhibit or induce UGTs. In vitro studies have shown that chloramphenicol can inhibit metabolism mediated by CYPs 3A4 (strong), 2C19 (strong) and 2D6 (weak). Concentrations of neratinib may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity should be considered. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the absorbed concentrations are unlikely to cause a clinically relevant interaction.",See Summary
63,Neratinib,Chlordiazepoxide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolised by CYP3A4, but does not inhibit or induce cytochromes. Neratinib does not inhibit or induce CYPs.",See Summary
64,Neratinib,Chlorphenamine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolised in the liver via CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
65,Neratinib,Chlorpromazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolised mainly by CYP2D6, but also by CYP1A2. Neratinib does not inhibit or induce CYPs.",See Summary
66,Neratinib,Chlortalidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Neratinib does not interact with this metabolic pathway.,See Summary
67,Neratinib,Ciclosporin (Cyclosporine),"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ciclosporin is a substrate of CYP3A4 and P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of ciclosporin may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for ciclosporin toxicity is recommended. Furthermore, ciclosporin inhibits CYP3A4 and OATP1B1. Concentrations of neratinib may increase due to CYP3A4 inhibition. The clinical relevance of this interaction is unknown. Therefore, coadministration is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity and a dose reduction of neratinib should be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
68,Neratinib,Cilazapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
69,Neratinib,Cimetidine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Cimetidine is metabolised by CYP450 enzymes. Neratinib does not inhibit or induce CYPs. In vitro data indicate that cimetidine inhibits OAT1 and OCT2 but at concentrations much higher than the observed clinical concentrations. Cimetidine is also a weak inhibitor of CYPs 3A4, 1A2, 2D6 and 2C19. Neratinib concentrations may increase due to CYP3A4 inhibition. The clinical relevance of this interaction is unknown. If coadministration is unavoidable, monitor closely for neratinib toxicity. Furthermore, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with cimetidine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of cimetidine. Monitor neratinib plasma concentrations, if available. ",See Summary
70,Neratinib,Ciprofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ciprofloxacin is primarily eliminated unchanged in the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolised and partially cleared through the bile and intestine. Neratinib is unlikely to interfere with this elimination pathway. Ciprofloxacin is also a weak to moderate inhibitor of CYP3A4 and a strong inhibitor of CYP1A2. Concentrations of neratinib may increase due to inhibition of CYP3A4. Therefore, coadministration is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity. A dose reduction of neratinib should also be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
71,Neratinib,Cisapride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisapride is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
72,Neratinib,Citalopram,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolised by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Neratinib does not inhibit or induce CYPs.",See Summary
73,Neratinib,Clarithromycin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Clarithromycin is metabolised by CYP3A4 and is also an inhibitor of CYP3A4 (strong) and P-gp. Neratinib does not inhibit or induce CYPs. However, concentrations of neratinib may increase due to inhibition of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with clarithromycin. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
74,Neratinib,Clavulanic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolised (likely non-CYP mediated pathway) and excreted in the urine by glomerular filtration. Neratinib is unlikely to interact with this elimination pathway.,See Summary
75,Neratinib,Clemastine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clemastine is predominantly metabolised in the liver via CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
76,Neratinib,Clindamycin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Clindamycin is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs. Furthermore, in vitro data suggest that clindamycin is a CYP3A4 inhibitor and may increase concentrations of neratinib. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity may be required.",See Summary
77,Neratinib,Clobetasol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of clobetasol.,See Summary
78,Neratinib,Clofazimine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Clofazimine is largely excreted unchanged in the faeces. Neratinib does not interact with this elimination pathway. Furthermore, in vitro data suggest that clofazimine is a CYP3A4 inhibitor and may increase concentrations of neratinib. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity may be required.",See Summary
79,Neratinib,Clofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolysed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Neratinib does not inhibit or induce OAT1.",See Summary
80,Neratinib,Clomipramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolised by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Clomipramine and desmethylclomipramine are both metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.",See Summary
81,Neratinib,Clonidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in the form of the unchanged parent drug (40-60% of the dose). Clonidine is also a weak inhibitor of OCT2. Neratinib does not interfere with the elimination of clonidine is not a substrate of OCT2.",See Summary
82,Neratinib,Clopidogrel,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug and is converted to its active metabolite mainly through CYP2C19 with CYPs 3A4, 2B6 and 1A2 playing a minor role. Neratinib does not inhibit or induce CYPs. Furthermore, clopidogrel is an inhibitor of CYP2C8 (strong), CYP2B6 (weak) and of CYP2C9 (in vitro) at high concentrations. The clinical relevance of CYP2C9 inhibition by clopidogrel is unknown. Neratinib is not metabolised by these CYPs.",See Summary
83,Neratinib,Clorazepate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolised to oxazepam by CYP3A4. Oxazepam is mainly glucuronidated. Neratinib does not inhibit or induce CYPs or UGTs. ,See Summary
84,Neratinib,Cloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
85,Neratinib,Clozapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. Neratinib does not inhibit or induce CYPs.",See Summary
86,Neratinib,Codeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine is converted via CYP2D6 to morphine, an active metabolite with analgesic and opioid properties. Morphine is further metabolised by conjugation with glucuronic acid to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active). Codeine is converted via CYP3A4 to norcodeine, an inactive metabolite. Neratinib does not inhibit or induce CYPs or UGTs. Additionally, the metabolite morphine is a substrate of P-gp. Neratinib is an in vitro an inhibitor of P-gp. However, no clinically relevant interaction is expected as the systemic exposure of neratinib is too low to inhibit systemic P-gp. ",See Summary
87,Neratinib,Colchicine,"
Potential Interaction
","
Very Low
",Coadministration has not been studied. Colchicine is metabolised by CYP3A4 and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Colchicine concentrations may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for colchicine toxicity is recommended.,See Summary
88,Neratinib,Cycloserine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly renally excreted via glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
89,Neratinib,Dabigatran,"
Potential Interaction
","
Very Low
",Coadministration has not been studied. Dabigatran is transported via P-gp and is renally excreted. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for dabigatran toxicity is recommended.,See Summary
90,Neratinib,Dalteparin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys and is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp. However, for administration routes other than oral, no clinically significant interaction is expected as the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
91,Neratinib,Dapsone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP450 enzymes. Neratinib does not inhibit or induce CYPs.",See Summary
92,Neratinib,Desipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
93,Neratinib,Desogestrel,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
94,Neratinib,Dexamethasone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4. Neratinib does not inhibit or induce CYPs. However, dexamethasone has been described as a weak inducer of CYP3A4 and may decrease neratinib plasma concentrations. The clinical relevance of this interaction is not known as the induction of CYP3A4 by dexamethasone has not yet been established. Monitoring of neratinib efficacy may be required.",See Summary
95,Neratinib,Dextropropoxyphene,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
96,Neratinib,Diamorphine (diacetylmorphine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolised by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Neratinib does not inhibit or induce UGTS. Additionally, morphine is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp. However, no clinically significant interaction is expected as the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
97,Neratinib,Diazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolised to nordiazepam (by CYP3A4 and CYP2C19) and to temazepam (mainly by CYP3A4). Temazepam is mainly glucuronidated. Neratinib does not inhibit or induce CYPs or UGTs. ,See Summary
98,Neratinib,Diclofenac,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidised by CYP2C9. Neratinib does not inhibit or induce CYPs or UGTs.,See Summary
99,Neratinib,Digoxin,"
Potential Weak Interaction
","
Low
","Digoxin is renally eliminated via OATP4C1 and P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Coadministration of digoxin and neratinib increased digoxin AUC and Cmax by 32% and 54%, respectively. Monitoring for digoxin toxicity should be considered.",See Summary
100,Neratinib,Dihydrocodeine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism. Neratinib does not inhibit or induce UGTs or CYPs.",See Summary
101,Neratinib,Diltiazem,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Diltiazem is metabolised by CYP3A4 and CYP2D6. Neratinib does not inhibit or induce CYPs. Diltiazem is a moderate inhibitor of CYP3A4 and may increase concentrations of neratinib. Therefore, coadministration with diltiazem is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity and a dose reduction of neratinib should be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
102,Neratinib,Diphenhydramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 1A2, 2C9 and 2C19. Diphenhydramine is also a weak inhibitor of CYP2D6. Neratinib does not interact with this pathway.",See Summary
103,Neratinib,Dipyridamole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Neratinib does not inhibit or induce UGTs. ",See Summary
104,Neratinib,Disopyramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is metabolised by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine. Neratinib does not inhibit or induce CYPs.,See Summary
105,Neratinib,Dolasetron,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolised by CYP2D6 (10-20%) and CYP3A4 (<1%). Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
106,Neratinib,Domperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Domperidone is mainly metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
107,Neratinib,Dopamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Neratinib is unlikely to interact with this metabolic pathway.",See Summary
108,Neratinib,Doxazosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolised mainly by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
109,Neratinib,Doxepin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolised to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Doxepin and nordoxepin are both metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
110,Neratinib,Doxycycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40-60% of an administered dose can be accounted for in the urine. Neratinib does not interact with this elimination pathway.,See Summary
111,Neratinib,Dronabinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolised by CYP2C9 and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
112,Neratinib,Drospirenone,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolised to a minor extent via CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
113,Neratinib,Dulaglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is degraded by endogenous endopeptidases. Dulaglutide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. The clinical relevance of delayed absorption is considered to be limited.,See Summary
114,Neratinib,Duloxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolised by CYP2D6 and CYP1A2. Neratinib does not inhibit or induce CYPs.,See Summary
115,Neratinib,Dutasteride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
116,Neratinib,Dydrogesterone,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolised to dihydrodydrogesterone (possibly via CYP3A4). Neratinib does not inhibit or induce CYPs.,See Summary
117,Neratinib,Edoxaban,"
Potential Interaction
","
Very Low
",Coadministration has not been studied. Edoxaban is partially metabolised by CYP3A4 (<10%) and is transported via P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for edoxaban toxicity is recommended.,See Summary
118,Neratinib,Eltrombopag,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (via UGT1A1 and UGT1A3) and oxidation (via CYP1A2 and CYP2C8). Neratinib does not inhibit or induce UGTs or CYPs.,See Summary
119,Neratinib,Enalapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is renally eliminated (possibly via OATs). Neratinib is unlikely to interfere with this elimination pathway.  ,See Summary
120,Neratinib,Enoxaparin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is predominantly renally excreted. Neratinib does not interact with this metabolic pathway. ",See Summary
121,Neratinib,Eprosartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eprosartan is largely excreted in bile and urine as unchanged drug. Neratinib is unlikely to interfere with this elimination pathway. ,See Summary
122,Neratinib,Ertapenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
123,Neratinib,Erythromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Erythromycin is a substrate of CYP3A4 and P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. As the clinical relevance of this interaction is unknown, monitoring for erythromycin toxicity should be considered. Furthermore, erythromycin is an inhibitor of CYP3A4 (moderate) and P-gp. Concentrations of neratinib may increase due to inhibition of CYP3A4. Therefore, coadministration with erythromycin is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity. A dose reduction of neratinib should be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
124,Neratinib,Escitalopram,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolised by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Neratinib does not inhibit or induce CYPs.",See Summary
125,Neratinib,Esomeprazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Esomeprazole is metabolised by CYP2C19 and CYP3A4, and is also an inhibitor of CYP2C19. Neratinib does not interact with this pathway. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with esomeprazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of esomeprazole. Monitor neratinib plasma concentrations, if available. ",See Summary
126,Neratinib,Estazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolised to its major metabolite 4-hydroxyestazolam via CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
127,Neratinib,Estradiol,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolised by CYP3A4, CYP1A2 and is glucuronidated. Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
128,Neratinib,Ethambutol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolised by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%). Neratinib does not interact with this metabolic pathway.,See Summary
129,Neratinib,Ethinylestradiol,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethinylestradiol undergoes oxidation (CYP3A4>CYP2C9), sulfation and glucuronidation (UGT1A1). Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
130,Neratinib,Ethionamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolised in the liver; animal studies suggest involvement of flavin-containing monooxygenases. Neratinib does not interact with this metabolic pathway.,See Summary
131,Neratinib,Etonogestrel,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
132,Neratinib,Everolimus (Immunosuppressant),"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Everolimus is mainly metabolised by CYP3A4 and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for everolimus toxicity is recommended. Monitor everolimus plasma concentrations, if available. For administration routes other than oral, no clinically relevant interaction is expected, since the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
133,Neratinib,Exenatide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exenatide is cleared mainly by glomerular filtration. Exenatide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. The clinical relevance of delayed absorption is considered to be limited.,See Summary
134,Neratinib,Ezetimibe,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Neratinib does not inhibit or induce UGTs.,See Summary
135,Neratinib,Famotidine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Famotidine is excreted via OAT1/OAT3. Neratinib does not inhibit or induce OATs. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with famotidine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of famotidine. Monitor neratinib plasma concentrations, if available.",See Summary
136,Neratinib,Felodipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
137,Neratinib,Fenofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolysed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. Neratinib does not interact with this pathway.",See Summary
138,Neratinib,Fentanyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Neratinib does not inhibit or induce CYPs.,See Summary
139,Neratinib,Fexofenadine,"
Potential Weak Interaction
","
Very Low
",Coadministration has not been studied. Fexofenadine is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of fexofenadine may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary for fexofenadine. Monitoring for fexofenadine toxicity should be considered.,See Summary
140,Neratinib,Finasteride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
141,Neratinib,Fish oils,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
142,Neratinib,Flecainide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolised mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also renally eliminated unchanged. Neratinib does not inhibit or induce CYPs.",See Summary
143,Neratinib,Flucloxacillin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Flucloxacillin is mainly renally eliminated partly by glomerular filtration and partly by active secretion via OAT1. Neratinib is unlikely to interfere with this elimination pathway. Furthermore, flucloxacillin has been described as a CYP3A4 inducer. However, the mechanism and clinical relevance of this interaction is unknown. Concentrations of neratinib may decrease and monitoring of neratinib efficacy may be required.",See Summary
144,Neratinib,Fluconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Fluconazole is cleared primarily by renal excretion. Neratinib does not interfere with this elimination pathway. Fluconazole is also an inhibitor of CYPs 3A4 (moderate), 2C9 (moderate) and 2C19 (strong). Concentrations of neratinib may increase due to CYP3A4 inhibition. Therefore, coadministration with fluconazole should is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity and a dose reduction of neratinib should be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
145,Neratinib,Flucytosine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil (5-FU). 5-FU is further metabolised by dihydropyrimidine dehydrogenase (DPD) to an inactive metabolite. Neratinib does not interfere with this elimination pathway.,See Summary
146,Neratinib,Fludrocortisone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolised in the liver to inactive metabolites, possibly via CYP3A. Neratinib does not inhibit or induce CYPs.",See Summary
147,Neratinib,Flunitrazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolised mainly via CYP3A4 and CYP2C19. Neratinib does not inhibit or induce CYPs.,See Summary
148,Neratinib,Fluoxetine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is mainly metabolised by CYP2D6 and CYP2C9, and to a lesser extent by CYP2C19 and CYP3A4 to form norfluoxetine. Fluoxetine is a strong inhibitor of CYP2D6 and CYP2C19. Neratinib does not inhibit or induce CYPs and is not metabolised by CYP2D6 or CYP2C19.",See Summary
149,Neratinib,Fluphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
150,Neratinib,Flurazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Neratinib does not inhibit or induce CYPs.,See Summary
151,Neratinib,Fluticasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs. Note: A clinically relevant interaction is not expected with the topical use of fluticasone.,See Summary
152,Neratinib,Fluvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolised by CYP2C9 (75%) and to a lesser extent by CYP3A4 (20%) and CYP2C8 (5%). Neratinib does not inhibit or induce CYPs. Furthermore, fluvastatin potentially inhibits CYP2C9, but the clinical relevance of CYP2C9 inhibition is unknown. Neratinib is not a substrate of CYP2C9.",See Summary
153,Neratinib,Fluvoxamine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Fluvoxamine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Neratinib does not inhibit or induce CYPs. However, fluvoxamine is also an inhibitor of CYPs 1A2 (strong), 2C19 (strong), 3A4 (moderate), 2C9 (weak-moderate) and 2D6 (weak). Concentrations of neratinib may increase due to inhibition of CYP3A4. Therefore, coadministration with fluvoxamine is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity and a dose reduction of neratinib should be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
154,Neratinib,Fondaparinux,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is predominantly renally eliminated. Neratinib does not interact with this elimination pathway.,See Summary
155,Neratinib,Formoterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation. As multiple CYP450 and UGT enzymes catalyse the transformation the potential for a pharmacokinetic interaction is low. Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
156,Neratinib,Fosaprepitant,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Fosaprepitant is rapidly, almost completely, converted to the active metabolite aprepitant. Neratinib does not interact with this pathway. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Neratinib does not inhibit or induce CYPs. However, during treatment aprepitant is a moderate inhibitor of CYP3A4. Concentrations of neratinib may increase during the three days of coadministration due to CYP3A4 inhibition. Coadministration should be approached with caution. If coadministration is unavoidable, monitor closely for neratinib toxicity. After treatment, aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of neratinib may decrease due to CYP3A4 induction, but this is unlikely to be of clinical relevance.",See Summary
157,Neratinib,Fosphenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Fosphenytoin is rapidly converted to the active metabolite phenytoin. Neratinib does not interact with this pathway. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Neratinib does not inhibit or induce CYPs. However, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with fosphenytoin. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
158,Neratinib,Furosemide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also renally eliminated unchanged (via OATs). Neratinib does not inhibit or induce UGTs or OATs. In vitro data indicate that furosemide is an inhibitor of the renal transporters OAT1/OAT3. Neratinib is not a substrate of OATs.,See Summary
159,Neratinib,Gabapentin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
160,Neratinib,Gemfibrozil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Neratinib does not inhibit or induce UGTs. Furthermore, gemfibrozil is an inhibitor of CYP2C8 (strong), OATP1B1 and OAT3. In vitro data indicate gemfibrozil to be a strong inhibitor of CYP2C9 but in vivo data showed no clinically relevant effect on CYP2C9. Neratinib is not a substrate of these CYPs, OATs or OATPs.",See Summary
161,Neratinib,Gentamicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
162,Neratinib,Gestodene,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Neratinib does not inhibit or induce CYPs.,See Summary
163,Neratinib,Glibenclamide (Glyburide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
164,Neratinib,Gliclazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C19. Neratinib does not inhibit or induce CYPs.,See Summary
165,Neratinib,Glimepiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is mainly metabolised by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
166,Neratinib,Glipizide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolised by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
167,Neratinib,Granisetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Granisetron is metabolised by CYP3A4. Granisetron is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Concentrations of granisetron may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring for granisetron toxicity should be considered. For administration routes other than oral, no clinically relevant interaction is expected, since the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
168,Neratinib,Grapefruit juice,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Grapefruit juice is a known inhibitor of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with grapefruit juice.",See Summary
169,Neratinib,Green tea,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
170,Neratinib,Griseofulvin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. Griseofulvin is also a liver microsomal enzyme inducer and may lower plasma levels, and therefore reduce the efficacy of concomitantly administered medicinal products that are metabolised by CYP3A4, such as neratinib. Closely monitor neratinib efficacy.",See Summary
171,Neratinib,Haloperidol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGTs 2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4 and CYP2D6). Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
172,Neratinib,Heparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. Neratinib does not interact with this metabolic pathway.,See Summary
173,Neratinib,Hydralazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Neratinib does not interact with this metabolic pathway. In vitro studies have suggested that hydralazine is a mixed enzyme inhibitor, which may weakly inhibit CYP3A4 and CYP2D6. Concentrations of neratinib may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity may be required.",See Summary
174,Neratinib,Hydrochlorothiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised but is cleared by the kidneys via OAT1. In vitro data indicate that hydrochlorothiazide is unlikely to inhibit OAT1 in the range of clinically relevant drug concentrations. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Neratinib does not interact with this pathway.,See Summary
175,Neratinib,Hydrocodone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Neratinib does not inhibit or induce CYPs.",See Summary
176,Neratinib,Hydrocortisone (oral),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
177,Neratinib,Hydrocortisone (topical),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of hydrocortisone. ,See Summary
178,Neratinib,Hydromorphone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Neratinib does not inhibit or induce UGTs.",See Summary
179,Neratinib,Hydroxyurea (Hydroxycarbamide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyurea is metabolised in the liver and cleared via the lungs and kidneys. Neratinib does not interact with this metabolic pathway.,See Summary
180,Neratinib,Hydroxyzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolised by alcohol dehydrogenase and partly by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
181,Neratinib,Ibandronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ibandronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid.",See Summary
182,Neratinib,Ibuprofen,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Neratinib does not inhibit or induce CYPs or UGTs.,See Summary
183,Neratinib,Iloperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
184,Neratinib,Imipenem/Cilastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and to a lesser extent by active tubular secretion. Neratinib is unlikely to interfere with the elimination of imipenem/cilastatin.,See Summary
185,Neratinib,Imipramine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolised by CYPs 3A4, 2C19 and 1A2 to desipramine. Imipramine and desipramine are both metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.",See Summary
186,Neratinib,Indapamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolised by CYP450s. Neratinib does not inhibit or induce CYPs. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Neratinib does not interact with this pathway.,See Summary
187,Neratinib,Insulin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
188,Neratinib,Interferon alpha,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
189,Neratinib,Interleukin 2 (Aldesleukin),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. Neratinib does not interact with this elimination pathway.,See Summary
190,Neratinib,Ipratropium bromide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. Neratinib does not interact with this metabolic pathway.,See Summary
191,Neratinib,Irbesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolised by glucuronidation and oxidation (mainly CYP2C9). Neratinib does not inhibit or induce CYPs.,See Summary
192,Neratinib,Iron supplements,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
193,Neratinib,Isoniazid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Neratinib does not interact with this metabolic pathway.,See Summary
194,Neratinib,Isosorbide dinitrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. Neratinib does not inhibit or induce CYPs.,See Summary
195,Neratinib,Itraconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Itraconazole is primarily metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs. Itraconazole is also an inhibitor of CYP3A4 (strong), CYP2C9 (weak), P-gp and BCRP. Concentrations of neratinib may increase due to inhibition of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with itraconazole. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
196,Neratinib,Ivabradine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
197,Neratinib,Kanamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration. Neratinib does not interfere with this elimination pathway.,See Summary
198,Neratinib,Ketoconazole,"
Do Not Coadminister
","
Low
","Coadministration should be avoided. Ketoconazole is a substrate of CYP3A4. Neratinib does not inhibit or induce CYPs. However, ketoconazole is an inhibitor of CYP3A4 (strong) and P-gp. Coadministration with ketoconazole substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
199,Neratinib,Labetalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated (via UGT1A1 and UGT2B7). Neratinib does not inhibit or induce UGTs.,See Summary
200,Neratinib,Lacidipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
201,Neratinib,Lactulose,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. Neratinib is unlikely to interfere with this metabolic pathway.,See Summary
202,Neratinib,Lansoprazole,"
Do Not Coadminister
","
Low
","Coadministration should be avoided. Lansoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and lansoprazole decreased neratinib exposure by ~65%. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of lansoprazole. Monitor neratinib plasma concentrations, if available.",See Summary
203,Neratinib,Lercanidipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
204,Neratinib,Levocetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
205,Neratinib,Levofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levofloxacin is renally eliminated mainly by glomerular filtration and active secretion (possibly OCT2). Neratinib does not interfere with this elimination pathway.,See Summary
206,Neratinib,Levomepromazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
207,Neratinib,Levonorgestrel,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Neratinib does not inhibit or induce CYPs or UGTs.,See Summary
208,Neratinib,Levonorgestrel (Emergency Contraception),"
Potential Interaction
","
Very Low
","Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. However, the use of levonorgestrel as emergency contraception is a relative contraindication due to the risk of a pregnancy while having a hormone-sensitive tumour. Therefore, the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
209,Neratinib,Levothyroxine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolised by deiodination (by enzymes of deiodinase family) and glucuronidation. Neratinib does not interact with this metabolic pathway.,See Summary
210,Neratinib,Lidocaine (Lignocaine),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
211,Neratinib,Linagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor elimination pathway. Linagliptin is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. As the clinical relevance of this interaction is unknown, monitoring of blood glucose concentrations should be considered. Furthermore, linagliptin is a weak inhibitor of CYP3A4 and may increase concentrations of neratinib. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity is recommended.",See Summary
212,Neratinib,Linezolid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid undergoes non-CYP mediated metabolism. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
213,Neratinib,Liraglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Liraglutide is degraded by endogenous endopeptidases. Neratinib does not interact with this pathway.,See Summary
214,Neratinib,Lisinopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is renally eliminated unchanged via glomerular filtration. Neratinib does not interact with this elimination pathway.,See Summary
215,Neratinib,Lithium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. ,See Summary
216,Neratinib,Live vaccines,"
No Interaction Expected
","
Very Low
","Coadministration of live vaccines (such as BCG vaccine; measles, mumps and rubella vaccines; varicella vaccines; typhoid vaccines; rotavirus vaccines; yellow fever vaccines; oral polio vaccine) has not been studied. In patients, who are receiving cytotoxics or other immunosuppressant drugs, use of live vaccines for immunisation is contraindicated. However, no interaction between live vaccines and neratinib are expected.",See Summary
217,Neratinib,Loperamide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Loperamide is mainly metabolised by CYP3A4 and CYP2C8. Loperamide is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of loperamide may increase due to P-gp inhibition. As the clinical relevance of this interaction is unlikely, monitoring for loperamide toxicity may be required.",See Summary
218,Neratinib,Loratadine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
219,Neratinib,Lorazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam undergoes non-CYP-mediated elimination. Neratinib is unlikely to interfere with this metabolic pathway.,See Summary
220,Neratinib,Lormetazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated. Neratinib does not inhibit or induce UGTs.,See Summary
221,Neratinib,Losartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Neratinib does not inhibit or induce CYPs.,See Summary
222,Neratinib,Lovastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
223,Neratinib,Macitentan,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Neratinib does not inhibit or induce CYPs.",See Summary
224,Neratinib,Magnesium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
225,Neratinib,Maprotiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
226,Neratinib,Medroxyprogesterone (depot),"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
227,Neratinib,Medroxyprogesterone (non-depot),"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
228,Neratinib,Mefenamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolised by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9. Neratinib does not inhibit or induce CYPs or UGTs.,See Summary
229,Neratinib,Megestrol acetate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
230,Neratinib,Meropenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney with in vitro data suggesting it is a substrate of OAT3>OAT1. Neratinib does not inhibit or induce OAT1 or OAT3.,See Summary
231,Neratinib,Mesalazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolised to N-acetyl-mesalazine by N-acetyltransferase. Neratinib does not interact with this metabolic pathway.,See Summary
232,Neratinib,Metamizole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Metamizole is metabolised by hydrolysis to the active metabolite MAA in the gastrointestinal tract. Furthermore, metamizole is metabolised in serum and excreted via urine (90%) and faeces (10%). Neratinib does not interact with this pathway. However, metamizole is an inducer of CYP3A4 and may decrease neratinib concentrations. As the clinical relevance of this interaction is unknown, monitoring of neratinib efficacy is recommended.",See Summary
233,Neratinib,Metformin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine and is a substrate of OCT1/2/3, MATE1 and MATE2K. Neratinib does not interact with this metabolic pathway.",See Summary
234,Neratinib,Methadone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methadone is demethylated by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
235,Neratinib,Methyldopa,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. Neratinib does not interact with this elimination pathway.",See Summary
236,Neratinib,Methylphenidate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolised by CYP450s to a clinically relevant extent and does not inhibit or induce CYP450s. ,See Summary
237,Neratinib,Methylprednisolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
238,Neratinib,Metoclopramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolised by the CYP450 system (mainly CYP2D6). Neratinib does not inhibit or induce CYPs.,See Summary
239,Neratinib,Metolazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Neratinib does not interact with this pathway. ,See Summary
240,Neratinib,Metoprolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
241,Neratinib,Metronidazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Metronidazole is eliminated via glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway. Furthermore, elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, ciclosporin) with metronidazole. However, metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Since the mechanism of the interaction with CYP3A has not yet been identified, an interaction with neratinib cannot be excluded. Monitoring for neratinib toxicity may be required.",See Summary
242,Neratinib,Mexiletine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Neratinib does not inhibit or induce CYPs.,See Summary
243,Neratinib,Mianserin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolised by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs.",See Summary
244,Neratinib,Miconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Miconazole is extensively metabolised by the liver. Neratinib is unlikely to interfere with this unspecified pathway. Miconazole is also an inhibitor of CYP2C9 (moderate) and CYP3A4 (strong). Concentrations of neratinib may increase due to inhibition of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with miconazole. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available. Note: after dermal application miconazole is only minimally absorbed. No clinical relevant interaction is expected.",See Summary
245,Neratinib,Midazolam (oral),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
246,Neratinib,Midazolam (parenteral),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
247,Neratinib,Milnacipran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Neratinib does not interact with this metabolic pathway.",See Summary
248,Neratinib,Mirtazapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Neratinib does not inhibit or induce CYPs.",See Summary
249,Neratinib,Mometasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs. Note: A clinically relevant interaction is not expected with the topical use of mometasone.,See Summary
250,Neratinib,Montelukast,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolised by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Neratinib does not inhibit or induce CYPs.,See Summary
251,Neratinib,Morphine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Monitoring for morphine toxicity should be considered.",See Summary
252,Neratinib,Moxifloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Neratinib does not inhibit or induce UGTs.,See Summary
253,Neratinib,Mycophenolate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. Neratinib does not inhibit or induce UGTs. Furthermore, the active metabolite of mycophenolate, mycophenolic acid, is an inhibitor of OAT1/OAT3. Neratinib is not a substrate of OAT1/OAT3.",See Summary
254,Neratinib,Nadroparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nadroparin is renally excreted by a nonsaturable mechanism. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
255,Neratinib,Nandrolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nandrolone is metabolised in the liver by alpha-reductase. Neratinib does not interact with this metabolic pathway.,See Summary
256,Neratinib,Naproxen,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Neratinib does not inhibit or induce UGTs or CYPs.,See Summary
257,Neratinib,Nateglinide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolised by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Neratinib does not inhibit or induce CYPs.,See Summary
258,Neratinib,Nebivolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
259,Neratinib,Nefazodone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Nefazodone is metabolised mainly by CYP3A4. Neratinib does not inhibit or induce CYPs. However, nefazodone is a strong inhibitor of CYP3A4 and may increase concentrations of neratinib. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with nefazodone. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
260,Neratinib,Nicardipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8. Neratinib does not inhibit or induce CYPs. Nicardipine is also a weak inhibitor of CYP3A4 and may increase concentrations of neratinib. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity is recommended.",See Summary
261,Neratinib,Nicotinamide (Niacinamide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolised by xanthine oxidase and aldehyde oxidase. Neratinib does not interact with this metabolic pathway.,See Summary
262,Neratinib,Nifedipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
263,Neratinib,Nimesulide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolised in the liver following multiple pathways including CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
264,Neratinib,Nisoldipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
265,Neratinib,Nitrendipine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolised mainly by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
266,Neratinib,Nitrofurantoin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolised in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug (30-40%). Neratinib does not inhibit or induce UGTs.,See Summary
267,Neratinib,Norelgestromin,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolised to norgestrel (possibly by CYP3A4). Neratinib does not inhibit or induce CYPs.,See Summary
268,Neratinib,Norethisterone (Norethindrone),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is extensively biotransformed, first by reduction and then by sulfate and glucuronide conjugation. Neratinib does not interact with this metabolic pathway.",See Summary
269,Neratinib,Norgestimate,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestimate is rapidly deacetylated to the active metabolite which is further metabolised via CYP450. Neratinib does not inhibit or induce CYPs.,See Summary
270,Neratinib,Norgestrel,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is mainly metabolised by CYP3A4 and is glucuronidated to a minor extent. Neratinib does not inhibit or induce CYPs or UGTs.,See Summary
271,Neratinib,Nortriptyline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolised mainly by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
272,Neratinib,Nystatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.",See Summary
273,Neratinib,Ofloxacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is renally eliminated unchanged by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Neratinib does not interfere with this elimination pathway.,See Summary
274,Neratinib,Olanzapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised mainly by CYP1A2 (major) and CYP2D6, but also by glucuronidation (UGT1A4). Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
275,Neratinib,Olmesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine. Neratinib does not interact with this pathway.,See Summary
276,Neratinib,Omeprazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Omeprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs. Omeprazole is also an inducer of CYP1A2 and an inhibitor of CYP2C19. Neratinib is not metabolised by these CYPs. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with omeprazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of omeprazole. Monitor neratinib plasma concentrations, if available. ",See Summary
277,Neratinib,Ondansetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ondansetron is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2D6. Ondansetron is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Concentrations of ondansetron may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring for ondansetron toxicity should be considered. No a priori dose adjustment is necessary for ondansetron. For administration routes other than oral, no clinically relevant interaction is expected, since the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
278,Neratinib,Oxazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated. Neratinib does not inhibit or induce UGTs.,See Summary
279,Neratinib,Oxcarbazepine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Oxcarbazepine is extensively metabolised to the active metabolite monohydroxyderivate (MHD) through cystolic enzymes. Neratinib does not interact with this metabolic pathway. However, both oxcarbazepine and MHD are inducers of CYP3A4 (moderate) and CYP3A5, and are inhibitors of CYP2C19. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with oxcarbazepine. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
280,Neratinib,Oxprenolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised via glucuronidation. Neratinib does not inhibit or induce UGTs.,See Summary
281,Neratinib,Oxycodone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally to noroxycodone via CYP3A and oxymorphone via CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
282,Neratinib,Paliperidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily renally eliminated (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. Neratinib does not inhibit or induce CYPs and is unlikely to interfere with the elimination of paliperidone.,See Summary
283,Neratinib,Palonosetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Palonosetron is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Palonosetron is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Concentrations of palonosetron may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring for palonosetron toxicity should be considered. No a priori dose adjustment is necessary for palonosetron. For administration routes other than oral, no clinically relevant interaction is expected, since the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
284,Neratinib,Pamidronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion.,See Summary
285,Neratinib,Pantoprazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Pantoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYPs 3A4, 2D6 and 2C9. Neratinib does not inhibit or induce CYPs. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with pantoprazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of pantoprazole. Monitor neratinib plasma concentrations, if available. ",See Summary
286,Neratinib,Para-aminosalicylic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
287,Neratinib,Paracetamol (Acetaminophen),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolised by glucuronidation (via UGTs 1A9 (major), 1A6, 1A1, and 2B15), sulfation, and to a lesser extent by oxidation (CYPs 2E1 (major), 1A2, 3A4 and 2D6). Neratinib does not inhibit or induce UGTs or CYPs.",See Summary
288,Neratinib,Paroxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolised by CYP2D6. Paroxetine is also an inhibitor of CYP2D6 (strong) and CYP2C9. Neratinib does not interact with this pathway.,See Summary
289,Neratinib,Peginterferon alfa-2a,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
290,Neratinib,Penicillins,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Neratinib does not interfere with this elimination pathway.,See Summary
291,Neratinib,Perazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is mainly metabolised by CYPs 1A2, 3A4 and 2C19, and to a lesser extent by CYPs 2C9, 2D6 and 2E1, with oxidation via FMO3. Neratinib does not inhibit or induce CYPs or FMO3.",See Summary
292,Neratinib,Periciazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterised but is likely to involve CYP2D6. Neratinib does not inhibit or induce CYPs. ,See Summary
293,Neratinib,Perindopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolised to other inactive metabolites. Elimination occurs predominantly via the urine. Neratinib does not interact with this metabolic pathway.,See Summary
294,Neratinib,Perphenazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
295,Neratinib,Pethidine (Meperidine),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolised mainly by CYP2B6 and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
296,Neratinib,Phenelzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolised by oxidation via monoamine oxidase and to a lesser extent by acetylation. Neratinib does not interact with this metabolic pathway.,See Summary
297,Neratinib,Phenobarbital (Phenobarbitone),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Phenobarbital is metabolised by CYP2C19 and CYP2C9 (major) and to a lesser extent by CYP2E1. Neratinib does not inhibit or induce CYPs. However, phenobarbital is a strong inducer of CYPs 3A4, 2C9, 2C8 and UGTs. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with phenobarbital. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
298,Neratinib,Phenprocoumon,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is mainly metabolised by CYP2C9 and CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
299,Neratinib,Phenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Neratinib does not inhibit or induce CYPs. However, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with phenytoin. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
300,Neratinib,Phytomenadione (Vitamin K),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An in vitro study found that the only CYP450 enzyme involved in phytomenadione metabolism was CYP4F2. Neratinib does not inhibit or induce CYPs.,See Summary
301,Neratinib,Pimozide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is mainly metabolised by CYP3A4 and CYP2D6, and to a lesser extent by CYP1A2. Neratinib does not inhibit or induce CYPs.",See Summary
302,Neratinib,Pindolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolised to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Neratinib does not inhibit or induce CYPs and is unlikely to interfere with the elimination of pindolol.,See Summary
303,Neratinib,Pioglitazone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Neratinib does not inhibit or induce CYPs.",See Summary
304,Neratinib,Pipotiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
305,Neratinib,Piroxicam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolised by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
306,Neratinib,Pitavastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Pitavastatin is also a substrate of OATP1B1. Neratinib does not inhibit or induce UGTs, CYPs or OATP1B1.",See Summary
307,Neratinib,Posaconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Posaconazole is primarily metabolised by UGTs and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of posaconazole may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary for posaconazole. However, monitoring for posaconazole toxicity is recommended. Monitor posaconazole plasma concentrations, if available. Furthermore, posaconazole is a strong inhibitor of CYP3A4 and may increase neratinib concentrations. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with posaconazole. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
308,Neratinib,Potassium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is renally eliminated. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
309,Neratinib,Prasugrel,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6, and to a lesser extent by CYP2C9 and CYP2C19. Neratinib does not inhibit or induce CYPs.",See Summary
310,Neratinib,Pravastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pravastatin is minimally metabolised (via CYP3A4) and is a substrate of OATP1B1. Neratinib does not inhibit or induce CYPs or OATP1B1.,See Summary
311,Neratinib,Prazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin is extensively metabolised, primarily by demethylation and conjugation. Neratinib does not interact with this metabolic pathway.",See Summary
312,Neratinib,Prednisolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism via CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
313,Neratinib,Prednisone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolised by CYP3A4. Neratinib does not interact with this metabolic pathway.,See Summary
314,Neratinib,Pregabalin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pregabalin is cleared mainly by glomerular filtration (90% as unchanged drug). Neratinib is unlikely to interfere with this elimination pathway.,See Summary
315,Neratinib,Prochlorperazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Neratinib does not inhibit or induce CYPs.,See Summary
316,Neratinib,Promethazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolised by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
317,Neratinib,Propafenone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
318,Neratinib,Propranolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolised by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Neratinib does not inhibit or induce CYPs or UGTs.",See Summary
319,Neratinib,Prucalopride,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Prucalopride is minimally metabolised and mainly renally eliminated, partly by active secretion by renal transporters. Prucalopride is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. As the clinical relevance of this interaction is unknown, monitoring for prucalopride toxicity should be considered.",See Summary
320,Neratinib,Pyrazinamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolised by xanthine oxidase. Neratinib does not interact with this metabolic pathway.,See Summary
321,Neratinib,Pyridoxine (Vitamin B6),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
322,Neratinib,Quetiapine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is primarily metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
323,Neratinib,Quinapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Neratinib does not inhibit or induce OAT3.,See Summary
324,Neratinib,Quinidine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Quinidine is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2E1. Quinidine is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for quinidine toxicity is recommended. For administration routes other than oral, no clinically significant interaction is expected as the systemic exposure of neratinib is too low to inhibit systemic P-gp. Furthermore, quinidine is an inhibitor of CYP2D6 (strong), CYP3A4 (weak) and P-gp (moderate). Concentrations of neratinib may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity is recommended.",See Summary
325,Neratinib,Rabeprazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rabeprazole is mainly metabolised via non-enzymatic reduction and to a lesser extent by CYP2C19 and CYP3A4. Neratinib does not inhibit or induce CYPs. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with rabeprazole. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of rabeprazole. Monitor neratinib plasma concentrations, if available.",See Summary
326,Neratinib,Ramipril,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolised to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Neratinib does not interact with this metabolic pathway.",See Summary
327,Neratinib,Ranitidine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Ranitidine is excreted via OAT1/OAT3. Neratinib does not inhibit or induce OAT1/OAT3. However, the solubility of neratinib decreases with increasing pH of the stomach. Coadministration of neratinib and the proton pump inhibitor, lansoprazole, decreased neratinib exposure by ~65%. A similar effect may occur after coadministration with ranitidine. Therefore, coadministration should be avoided. If coadministration is clinically necessary, neratinib should be administered at the moment at which acid secretion is less inhibited, just before a new dose of ranitidine. Monitor neratinib plasma concentrations, if available.",See Summary
328,Neratinib,Ranolazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ranolazine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2D6. Ranolazine is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of ranolazine may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring of blood pressure should be considered. Ranolazine is a weak inhibitor of P-gp, CYP3A4 and CYP2D6. Concentrations of neratinib may increase due to inhibition of CYP3A4. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity is recommended.",See Summary
329,Neratinib,Reboxetine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs. Furthermore, in vitro data indicate reboxetine to be a weak inhibitor of CYP3A4 but in vivo data showed no inhibitory effect on CYP3A4. Therefore, no interaction is expected with neratinib.",See Summary
330,Neratinib,Repaglinide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolised by CYP2C8 and CYP3A4, with clinical data indicating it is a substrate of OATP1B1. Neratinib does not inhibit or induce CYPs or OATP1B1.",See Summary
331,Neratinib,Retinol (Vitamin A),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver but retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Neratinib does not interact with this pathway.",See Summary
332,Neratinib,Riboflavin (Vitamin B2),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
333,Neratinib,Rifabutin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Rifabutin is metabolised by CYP3A and via deacetylation. Neratinib does not interact with this metabolic pathway. However, rifabutin is a strong CYP3A4 and P-gp inducer. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with rifabutin. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
334,Neratinib,Rifampicin,"
Do Not Coadminister
","
Moderate
","Coadministration is contraindicated. Rifampicin is metabolised via deacetylation. Neratinib does not interact with this metabolic pathway. Rifampicin is also a strong CYP3A4 and P-gp inducer. Coadministration of neratinib and rifampicin decreased neratinib AUC by 87%. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
335,Neratinib,Rifapentine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. Rifapentine is metabolised via deacetylation. Neratinib does not interact with this pathway. Rifapentine is also a strong CYP3A4, CYP2C8 and P-gp inducer. Concentrations of neratinib may decrease due to induction of CYP3A4. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib AUC by 87%. A similar effect may occur after coadministration with rifapentine. Therefore, coadministration is contraindicated. Selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 is recommended. Increasing the dose of neratinib when co-administering with strong or moderate CYP3A inducers is unlikely to sufficiently compensate for the loss of exposure.",See Summary
336,Neratinib,Rifaximin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug. Neratinib does not interact with this elimination pathway.",See Summary
337,Neratinib,Risperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Risperidone is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Risperidone is also a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of risperidone may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. However, monitoring for risperidone toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected, since the systemic exposure of neratinib is too low to inhibit systemic P-gp.",See Summary
338,Neratinib,Rivaroxaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Rivaroxaban is partly metabolised in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine. Rivaroxaban is also a substrate of P-gp and BCRP. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for rivaroxaban toxicity is recommended.",See Summary
339,Neratinib,Rosiglitazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
340,Neratinib,Rosuvastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosuvastatin is largely excreted unchanged via the faeces via OATP1B1 and is also a substrate of BCRP. Neratinib does not inhibit or induce OATP1B1 or BCRP. ,See Summary
341,Neratinib,Salbutamol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolised to the inactive salbutamol-4’-O-sulphate. Neratinib is unlikely to interact with this metabolic pathway.,See Summary
342,Neratinib,Salmeterol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The systemic exposure of salmeterol is low. Salmeterol is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
343,Neratinib,Saxagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Saxagliptin is mainly metabolised by CYP3A4 and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of saxagliptin may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring of blood glucose concentrations should be considered.",See Summary
344,Neratinib,Senna,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces but also in other secretions. No clinically significant interactions are known.,See Summary
345,Neratinib,Sertindole,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertindole is metabolised by CYP2D6 and CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
346,Neratinib,Sertraline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolised by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Neratinib does not inhibit or induce CYPs.",See Summary
347,Neratinib,Sildenafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
348,Neratinib,Simvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolised by CYP3A4. Simvastatin is also a substrate of BCRP and the active metabolite is a substrate of OATP1B1. Neratinib does not inhibit or induce CYPs, OATP1B1 or BCRP.",See Summary
349,Neratinib,Sirolimus,"
Potential Interaction
","
Very Low
",Coadministration has not been studied. Sirolimus is metabolised by CYP3A4 and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Sirolimus concentrations may increase due to P-gp inhibition. The clinical relevance of this interaction is unknown. No a priori dose adjustment is necessary. Monitoring for sirolimus toxicity is recommended.,See Summary
350,Neratinib,Sitagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, and P-gp) and metabolism by CYP3A4 represents a minor metabolic pathway. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of sitagliptin may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring of blood glucose concentrations should be considered.",See Summary
351,Neratinib,Sodium nitroprusside,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. Neratinib does not interact with this metabolic pathway.",See Summary
352,Neratinib,Sotalol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sotalol is excreted unchanged via renal elimination. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
353,Neratinib,Spectinomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
354,Neratinib,Spironolactone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolised by the flavin containing monooxygenases. Neratinib does not interact with this metabolic pathway.,See Summary
355,Neratinib,Stanozolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Stanozolol undergoes hepatic metabolism. Neratinib is unlikely to interfere with this metabolic pathway.,See Summary
356,Neratinib,St John's Wort,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but is contraindicated. St John’s wort is a P-gp and CYP3A4 inducer. Concentrations of neratinib may decrease due to CYP3A4 induction. Coadministration of neratinib and the strong CYP3A4 inducer, rifampicin, decreased neratinib Cmax by 76% and AUC by 87%. A similar effect may occur after coadministration with St John’s Wort.",See Summary
357,Neratinib,Streptokinase,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Neratinib is unlikely to interfere with this elimination pathway.",See Summary
358,Neratinib,Streptomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is eliminated by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
359,Neratinib,Sulfadiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Neratinib does not inhibit or induce CYPs.,See Summary
360,Neratinib,Sulpiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
361,Neratinib,Tacrolimus,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Tacrolimus is metabolised mainly by CYP3A4. Neratinib does not inhibit or induce CYPs. Tacrolimus is also an inhibitor of CYP3A4 and OATP1B1 in vitro but produced modest inhibition of CYP3A4 and OATP1B1 in the range of clinical concentrations. Neratinib concentrations may increase due to CYP3A4 inhibition. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity may be required.",See Summary
362,Neratinib,Tadalafil (Pulmonary Arterial Hypertension),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
363,Neratinib,Tamsulosin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
364,Neratinib,Tazobactam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is excreted as unchanged drug (approximately 80%) and inactive metabolite (approximately 20%) in the urine. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
365,Neratinib,Telithromycin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Telithromycin is metabolised by CYP3A4 (50%) with the remaining 50% metabolised via non-CYP mediated pathways. Neratinib does not inhibit or induce CYPs. However, telithromycin is a strong inhibitor of CYP3A4 and may increase concentrations of neratinib. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2-fold and 4.8-fold, respectively. A similar effect may occur after coadministration with telithromycin. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
366,Neratinib,Telmisartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Neratinib does not inhibit or induce UGTs.,See Summary
367,Neratinib,Temazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Neratinib does not inhibit or induce UGTs.,See Summary
368,Neratinib,Terbinafine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolised by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYP2C8 and CYP2C19. Terbinafine is also a moderate-strong inhibitor of CYP2D6. Neratinib does not interact with this metabolic pathway.",See Summary
369,Neratinib,Testosterone,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
370,Neratinib,Tetracycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracycline is eliminated unchanged primarily by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
371,Neratinib,Theophylline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolised by CYP1A2. Neratinib does not inhibit or induce CYPs.,See Summary
372,Neratinib,Thiamine (Vitamin B1),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
373,Neratinib,Thioridazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
374,Neratinib,Tiapride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiapride is excreted largely unchanged in urine. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
375,Neratinib,Ticagrelor,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Ticagrelor is a substrate of CYP3A4 and P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. It is unknown if P-gp inhibition will lead to a clinically relevant effect on ticagrelor exposure. No a priori dose adjustment is necessary. Monitoring for ticagrelor toxicity is recommended. Ticagrelor is also a weak inhibitor of CYP3A4 and may increase concentrations of neratinib. As the clinical relevance of this interaction is unknown, monitoring for neratinib toxicity is recommended.",See Summary
376,Neratinib,Timolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
377,Neratinib,Tinzaparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is renally excreted as unchanged or almost unchanged drug. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
378,Neratinib,Tolbutamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C8 and CYP2C19. Neratinib does not inhibit or induce CYPs.,See Summary
379,Neratinib,Tolterodine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 and CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
380,Neratinib,Torasemide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolised mainly by CYP2C9. Neratinib does not inhibit or induce CYPs. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Neratinib does not interact with this pathway.",See Summary
381,Neratinib,Tramadol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolised by CYPs 3A4, 2B6, and 2D6. Neratinib does not inhibit or induce CYPs.",See Summary
382,Neratinib,Trandolapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat. Neratinib does not interact with this metabolic pathway.,See Summary
383,Neratinib,Tranexamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranexamic acid is mainly cleared by glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
384,Neratinib,Tranylcypromine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Neratinib does not interact with this metabolic pathway.,See Summary
385,Neratinib,Trazodone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
386,Neratinib,Triamcinolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
387,Neratinib,Triazolam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolised by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
388,Neratinib,Trimethoprim/Sulfamethoxazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. To a lesser extent (approximately 30%) trimethoprim is metabolised by CYP-enzymes (in vitro data suggest CYPs 3A4, 1A2 and 2C9). Neratinib does not inhibit or induce CYPs and is unlikely to interfere with the elimination of trimethoprim. Furthermore, trimethoprim is a weak CYP2C8 inhibitor and in vitro data suggest that trimethoprim is an inhibitor of OCT2 and MATE1. Sulfamethoxazole is metabolised via and is a weak inhibitor of CYP2C9. Neratinib does not interact with these pathways.",See Summary
389,Neratinib,Trimipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolised mainly by CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
390,Neratinib,Tropisetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Tropisetron is metabolised mainly by CYP2D6 and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect P-gp present in the gut. Concentrations of tropisetron may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring for tropisetron toxicity should be considered. No a priori dose adjustment is necessary for tropisetron.",See Summary
391,Neratinib,Ulipristal,"
Do Not Coadminister
","
Very Low
",Coadministration is contraindicated if neratinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
392,Neratinib,Valproic acid (Valproate),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproic acid is primarily metabolised by glucuronidation (50%) and mitochondrial beta-oxidation (30-40%). To a lesser extent (10%) valproic acid is metabolised by CYP2C9 and CYP2C19. Neratinib does not inhibit or induce UGTs or CYPs. In addition, valproic acid is an inhibitor of CYP2C9. Neratinib is not metabolised by CYP2C9.",See Summary
393,Neratinib,Valsartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is eliminated unchanged mostly through biliary excretion. Neratinib does not interact with this elimination pathway.,See Summary
394,Neratinib,Vancomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via glomerular filtration. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
395,Neratinib,Venlafaxine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Neratinib does not inhibit or induce CYPs.",See Summary
396,Neratinib,Verapamil,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Verapamil is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8 and 2C9. Neratinib does not inhibit or induce CYPs. Verapamil is also a moderate inhibitor of CYP3A4 and may increase concentrations of neratinib. Therefore, coadministration with verapamil is not recommended and selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for neratinib toxicity and a dose reduction of neratinib should be considered. Consider monitoring of neratinib plasma concentrations, if available.",See Summary
397,Neratinib,Vildagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Vildagliptin is inactivated via non-CYP mediated hydrolysis and is a substrate of P-gp. Neratinib is an in vitro inhibitor of P-gp at concentrations that are likely to only affect the P-gp present in the gut. Concentrations of vildagliptin may increase due to P-gp inhibition. As the clinical relevance of this interaction is unknown, monitoring of blood glucose concentrations should be considered.",See Summary
398,Neratinib,Vitamin E,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
399,Neratinib,Voriconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Voriconazole is metabolised by CYP2C19 (major) and to a lesser extent by CYP3A4 and CYP2C9. Neratinib does not inhibit or induce CYPs. However, voriconazole is a strong inhibitor of CYP3A4 and a weak inhibitor of CYPs 2C9, 2C19 and 2B6. Concentrations of neratinib may increase due to CYP3A4 inhibition. Coadministration of neratinib and the strong CYP3A4 inhibitor, ketoconazole, substantially increased neratinib Cmax and AUC by 3.2- and 4.8-fold, respectively. A similar effect may occur after coadministration with voriconazole. Therefore, coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 is recommended. If coadministration is unavoidable, monitor closely for neratinib toxicity. Monitor neratinib plasma concentrations, if available.",See Summary
400,Neratinib,Warfarin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and CYP3A4. S-warfarin (more potent) is metabolised by CYP2C9. Neratinib does not inhibit or induce CYPs.,See Summary
401,Neratinib,Xipamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Neratinib does not interact with this pathway.",See Summary
402,Neratinib,Zaleplon,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolised by aldehyde oxidase and to a lesser extent by CYP3A4. Neratinib does not inhibit or induce CYPs.,See Summary
403,Neratinib,Ziprasidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Neratinib does not inhibit or induce CYPs.",See Summary
404,Neratinib,Zoledronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zoledronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Neratinib is unlikely to interfere with this elimination pathway.,See Summary
405,Neratinib,Zolpidem,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 1A2. Neratinib does not inhibit or induce CYPs.",See Summary
406,Neratinib,Zopiclone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C8. Neratinib does not inhibit or induce CYPs.,See Summary
407,Neratinib,Zotepine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Neratinib does not inhibit or induce CYPs.,See Summary
408,Neratinib,Zuclopenthixol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolised by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. Neratinib does not interact with this metabolic pathway.",See Summary
